ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.75 USD
-0.39 (-2.04%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
ACADIA Pharmaceuticals Inc. [ACAD]
Reports for Purchase
Showing records 81 - 100 ( 246 total )
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
DRP Approval Unlikely Based on the Current Data Package
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
We Continue to Remain on the Sidelines; Reit Neutral and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
CRL Debacle Seemingly Pushes DRP Progression Years Into Future; PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
FDA Identified Deficiencies Present Cloud Around DRP Headway; PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
As DRP Steals the Show, Our Thoughts on Trofinetide
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department